Change in Certifying Accountants Form 8 K

Item 4.01.

Changes in Registrant's Certifying Accountant.

(b) Engagement of New Independent Registered Public Accounting Firm

On October 31, 2024, ADMA Biologics, Inc. (the "Company") and KPMG LLP ("KPMG") executed an agreement pursuant to which KPMG will initiate its engagement and serve as the Company's new independent registered public accounting firm effective upon the filing of the Company's Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2024. KPMG's engagement will include an audit of Company's consolidated financial statements for the fiscal year ending December 31, 2024, which will be filed as part of the Company's Annual Report on Form 10-K anticipated to be filed on or before March 3, 2025.

During the fiscal years ended December 31, 2023 and 2022 and the subsequent interim period through October 31, 2024, the Company did not consult with KPMG with respect to (a) the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that might be rendered with respect to the Company's financial statements, and no written report or oral advice was provided to the Company by KPMG that was an important factor considered by the Company in reaching a decision as to any accounting, auditing or financial reporting issue, or (b) any matter that was subject to any disagreement, as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions thereto, or a reportable event within the meaning set forth in Item 304(a)(1)(v) of Regulation S-K.